TerminatedPHASE1, PHASE2NCT05160168

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Theseus Pharmaceuticals
Principal Investigator
Stew Kroll
Theseus Pharmaceuticals (a subsidiary of Concentra Biosciences)
Intervention
THE-630(drug)
Enrollment
32 target
Eligibility
18 years · All sexes
Timeline
20222024

Study locations (7)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05160168 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor

← Back to all trials